KR102567012B1 - 피라졸 유도체의 폐섬유증 치료제 - Google Patents

피라졸 유도체의 폐섬유증 치료제 Download PDF

Info

Publication number
KR102567012B1
KR102567012B1 KR1020210162964A KR20210162964A KR102567012B1 KR 102567012 B1 KR102567012 B1 KR 102567012B1 KR 1020210162964 A KR1020210162964 A KR 1020210162964A KR 20210162964 A KR20210162964 A KR 20210162964A KR 102567012 B1 KR102567012 B1 KR 102567012B1
Authority
KR
South Korea
Prior art keywords
pulmonary fibrosis
compound
formula
pyridin
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020210162964A
Other languages
English (en)
Korean (ko)
Other versions
KR20210146871A (ko
Inventor
문성환
이수진
유현경
고유경
Original Assignee
압타바이오 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020210036863A external-priority patent/KR102386097B1/ko
Application filed by 압타바이오 주식회사 filed Critical 압타바이오 주식회사
Publication of KR20210146871A publication Critical patent/KR20210146871A/ko
Application granted granted Critical
Publication of KR102567012B1 publication Critical patent/KR102567012B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020210162964A 2020-04-13 2021-11-24 피라졸 유도체의 폐섬유증 치료제 Active KR102567012B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20200044598 2020-04-13
KR1020200044598 2020-04-13
KR1020210036863A KR102386097B1 (ko) 2020-04-13 2021-03-22 피라졸 유도체의 폐섬유증 치료제

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020210036863A Division KR102386097B1 (ko) 2020-04-13 2021-03-22 피라졸 유도체의 폐섬유증 치료제

Publications (2)

Publication Number Publication Date
KR20210146871A KR20210146871A (ko) 2021-12-06
KR102567012B1 true KR102567012B1 (ko) 2023-08-14

Family

ID=78083982

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020210162964A Active KR102567012B1 (ko) 2020-04-13 2021-11-24 피라졸 유도체의 폐섬유증 치료제
KR1020220032891A Pending KR20220039687A (ko) 2020-04-13 2022-03-16 피라졸 유도체의 폐섬유증 치료제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020220032891A Pending KR20220039687A (ko) 2020-04-13 2022-03-16 피라졸 유도체의 폐섬유증 치료제

Country Status (12)

Country Link
US (1) US12616684B2 (enExample)
EP (1) EP4137134A4 (enExample)
JP (1) JP7539485B2 (enExample)
KR (2) KR102567012B1 (enExample)
CN (1) CN115427039B (enExample)
AU (1) AU2021255160B2 (enExample)
BR (1) BR112022020649A2 (enExample)
CA (1) CA3172596A1 (enExample)
CL (1) CL2022002642A1 (enExample)
CO (1) CO2022014273A2 (enExample)
MX (1) MX2022012726A (enExample)
WO (1) WO2021210799A1 (enExample)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101302315B1 (ko) 2011-07-19 2013-08-30 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 호흡기 질환 예방 및 치료용 조성물
KR101821593B1 (ko) * 2017-02-23 2018-01-25 압타바이오 주식회사 안질환 치료제
KR101840702B1 (ko) 2017-11-01 2018-03-22 압타바이오 주식회사 간질환 치료제

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040094464A (ko) * 2003-05-02 2004-11-10 학교법인 이화학당 피리디닐 피라졸 유도체
KR20120054077A (ko) 2009-08-21 2012-05-29 길리아드 바이오로직스, 인크. 폐 섬유증 장애의 치료를 위한 방법 및 조성물
WO2011028043A2 (ko) 2009-09-02 2011-03-10 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
KR101633957B1 (ko) 2012-08-27 2016-06-27 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물
US10548911B2 (en) * 2014-06-16 2020-02-04 University Of Rochester Small molecule anti-scarring agents
US11096952B2 (en) * 2016-02-02 2021-08-24 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Chemicals and methods to prevent and treat TGF-beta mediated activation of fibroblasts to reduce and treat cancer and fibrosis
WO2017192304A1 (en) 2016-05-02 2017-11-09 Inception 1, Inc. Arylcarboxamides and uses thereof
CA3046158A1 (en) 2017-01-27 2018-08-02 Genfit Pharmaceutical compositions for combination therapy
IL268751B (en) 2017-03-13 2022-08-01 Genfit Pharmaceutical preparations for combined treatment
CN110536683A (zh) 2017-04-18 2019-12-03 基恩菲特公司 包含PPAR激动剂如伊拉非诺和乙酰CoA羧化酶ACC抑制剂的组合
KR101856444B1 (ko) 2017-04-20 2018-05-10 압타바이오 주식회사 3-페닐-4-프로필-1-(피리딘-2-일)-1ｈ-피라졸-5-올 염산염의 신규 결정형 고체 화합물
TWI815938B (zh) 2018-08-01 2023-09-21 日商日本化藥股份有限公司 具有n-烷基的芳香族胺樹脂、硬化性樹脂組成物及其硬化物
EP3628669A1 (en) 2018-09-28 2020-04-01 GenKyoTex Suisse SA Novel compounds as nadph oxidase inhibitors
KR102207340B1 (ko) 2018-10-19 2021-01-22 한남대학교 산학협력단 표면 개질된 다공성 탄소복합소재 및 그 제조방법
CN109912600B (zh) * 2019-02-22 2021-08-03 四川大学华西医院 一种防治肺纤维化的咪唑并嘧啶类衍生物及其应用
MX2022012472A (es) 2020-04-08 2022-12-15 Aptabio Therapeutics Inc Agente para el tratamiento de lesion renal aguda inducida por medio de contraste.
WO2021263281A2 (en) * 2020-06-26 2021-12-30 Ann And Robert H. Lurie Children's Hospital Of Chicago Methods and compositions for the treatment of covid-19 and associated respiratory distress and multi-organ failure, sepsis, acute respiratory distress syndrome, and cordiovascular diseases
UY39671A (es) 2021-03-15 2022-10-31 Novartis Ag Derivados de pirazolopiridina y sus usos.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101302315B1 (ko) 2011-07-19 2013-08-30 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 호흡기 질환 예방 및 치료용 조성물
KR101821593B1 (ko) * 2017-02-23 2018-01-25 압타바이오 주식회사 안질환 치료제
KR101840702B1 (ko) 2017-11-01 2018-03-22 압타바이오 주식회사 간질환 치료제

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biomolecules & therapeutics, 2020 Jan, 28(1), 25-33*
Oncotarget, 2017, 8(43), 74217-74232*

Also Published As

Publication number Publication date
WO2021210799A1 (ko) 2021-10-21
JP7539485B2 (ja) 2024-08-23
KR20210146871A (ko) 2021-12-06
EP4137134A1 (en) 2023-02-22
US20230148365A1 (en) 2023-05-11
MX2022012726A (es) 2022-11-07
KR20220039687A (ko) 2022-03-29
CN115427039B (zh) 2025-04-04
BR112022020649A2 (pt) 2022-11-29
AU2021255160B2 (en) 2024-02-01
CA3172596A1 (en) 2021-10-21
JP2023522628A (ja) 2023-05-31
CL2022002642A1 (es) 2023-06-16
EP4137134A4 (en) 2024-08-07
CO2022014273A2 (es) 2022-10-21
AU2021255160A1 (en) 2022-10-06
US12616684B2 (en) 2026-05-05
CN115427039A (zh) 2022-12-02

Similar Documents

Publication Publication Date Title
JP7492002B2 (ja) Ｌｓｄ１阻害剤によりｌｓｄ１関連疾患及び障害を治療する方法
US20230414647A1 (en) Methods for the use of 5'-adenosine diphosphate ribose (adpr)
EP3592430B1 (en) Antimicrobial compounds, compositions, and uses thereof
JP5457196B2 (ja) Ｃｎｄａｃ（２’−シアノ−２’−デオキシ−ｎ４−パルミトイル−１−ベータ−ｄ−アラビノフラノシル−シトシン）及び細胞毒性薬を含む組合せ
US20110166149A1 (en) Pteridine derivatives for treating respiratory disease
KR102386097B1 (ko) 피라졸 유도체의 폐섬유증 치료제
US20180369188A1 (en) Application of phosphodiesterase 4 inhibitor zl-n-91 in preparation of medications for lung cancer proliferation and metastasis
US12616684B2 (en) Pulmonary fibrosis medicine containing pyrazole derivative
JP7749661B2 (ja) 心不全の処置のためのクロマノール化合物
RU2817989C1 (ru) Средство для лечения фиброза легких, содержащее производное пиразола
WO2021202947A1 (en) Method for treating lung disease with cell-free amniotic fluid
EP1908473B1 (en) Clarithromycin or salt thereof for use in the treatment pulmonary emphysema
KR20230031304A (ko) 폐섬유화증 치료용 조성물
JP2023514837A (ja) 線維症を治療するためのシクロスポリン類似体の使用
KR102595271B1 (ko) 니클로스아마이드 및 수니티닙을 포함하는 신장암 예방 또는 치료용 약학적 조성물
KR102961523B1 (ko) Pad 저해제를 포함하는 퇴행성 판막 질환의 예방 또는 치료용 조성물
US10364230B2 (en) Chromene-2 derivatives and use thereof in the treatment of fibrosis
CN114569615B (zh) 甲氨蝶呤类似物用于治疗炎症性皮肤疾病的用途
KR20260060207A (ko) 펜타데카노산 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 특발성 폐섬유증 예방 또는 치료용 약학적 조성물
CN117562915A (zh) 一种腺苷衍生物在制备预防、缓解或治疗纤维化疾病的药物中的应用
HK40099388A (en) Methods for the use of 5'-adenosine diphosphate ribose (adpr)
HK40041244B (en) Methods for the use of 5'-adenosine diphosphate ribose (adpr)
HK40041244A (en) Methods for the use of 5'-adenosine diphosphate ribose (adpr)

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0107 Divisional application

Comment text: Divisional Application of Patent

Patent event date: 20211124

Patent event code: PA01071R01D

Filing date: 20210322

Application number text: 1020210036863

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230529

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230808

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230809

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230809

End annual number: 3

Start annual number: 1

PG1601 Publication of registration